Evolution of the Average Target: Afya Limited

Evolution of the Average Target - Afya Limited

Evolution of the Target Price: Afya Limited

Evolution of the Target Price - Afya Limited

Changes in Analyst Recommendations: Afya Limited

53a86b9df23884.jbgUgsisNV5Hw_wyqkx5oPu5LzakbyIBko7DQ0DuGHk.5tNh8IzrcG8qrp9q-Co_1sjyZ0KSME1u5cruLyymdBq_8lLxmPoBKD6Slw~ed04c67e73bbfacc430236cc21480c92
Nov. 05 Morgan Stanley Upgrades Afya to Equalweight From Underweight, Price Target is $12.60 MT
Nov. 03 Citigroup Upgrades Afya to Buy From Neutral, $12 Price Target MT
Oct. 29 BofA Securities Upgrades Afya to Buy From Neutral MT
Oct. 07 Afya Shares Rise After JPMorgan Upgrade MT
Oct. 07 JPMorgan Upgrades Afya to Overweight From Neutral, $19 Price Target MT
Feb. 24 BofA Securities Downgrades Afya to Neutral From Buy, Price Target is $17 MT
Feb. 13 Afya Shares Fall After Morgan Stanley Downgrade MT
Feb. 13 Morgan Stanley Downgrades Afya to Underweight From Equalweight, Adjusts Price Target to $16 From $17.50 MT
Jan. 16 UBS Downgrades Afya to Neutral From Buy, Adjusts PT to $16 From $18 MT
Jan. 08 UBS Trims Afya Price Target to $18 From $19, Maintains Buy Rating MT
Jan. 07 JPMorgan Downgrades Afya to Neutral From Overweight, Adjusts Price Target to $22 From $24.50 MT
25-09-08 UBS Upgrades Afya to Buy From Neutral, $19 Price Target MT
25-09-08 JPMorgan Upgrades Afya to Overweight, Price Target is $24.50 MT
25-08-06 Afya Shares Rise After Morgan Stanley Upgrade MT
25-08-06 Morgan Stanley Upgrades Afya to Equalweight From Underweight, Adjusts Price Target to $17.50 From $19 MT
25-07-29 Citigroup Upgrades Afya to Neutral From Sell, Adjusts Price Target to $14 From $16 MT
25-06-12 UBS Hikes Afya Price Target to $19.50 From $17.50, Maintains Neutral Rating MT
25-03-11 Morgan Stanley Downgrades Afya to Underweight From Equal Weight, Cuts Price Target to $17 From $19 MT
25-02-05 Bradesco BBI Downgrades Afya to Underperform From Neutral, Adjusts Price Target to $14 From $17 MT
25-01-31 Citigroup Downgrades Afya to Sell From Neutral, Adjusts Price Target to $15 From $18 MT
24-12-17 UBS Cuts Price Target on Afya to $17.50 From $19.50, Keeps Neutral Rating MT
24-08-30 UBS Initiates Coverage on Afya With Neutral Rating, Sets $19.50 Price Target MT
24-06-21 Morgan Stanley Adjusts Price Target on Afya to $19 From $21, Maintains Equalweight Rating MT
23-11-27 JPMorgan Downgrades Afya to Neutral From Overweight, Adjusts Price Target to $23 From $22 MT
22-11-22 Credit Suisse Adjusts Afya's Price Target to $18 From $19, Keeps Outperform Rating MT

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
- - -12.99%
+25.03%
+38.6%
+48.6%
+42.57%
+36.88%
+73.93%
+105.29%
Average +44.74%
Weighted average by Cap. +20.79%


Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
8
Last Close Price
59.10BRL
Average target price
87.01BRL
Spread / Average Target
+47.22%
High Price Target
101.49BRL
Spread / Highest target
+71.71%
Low Price Target
65.26BRL
Spread / Lowest Target
+10.41%

Analyst Consensus Detail

Analyst consensus - Afya Limited

Consensus revision (last 18 months)

Consensus revision (last 18 months) - Afya Limited
Trader
Investor
Global
Quality
ESG MSCI
-
MarketScreener Ratings - Afya Limited